Nektar Upsizes Public Offering to $325 Million, Prices Shares at $92.00
Summary
Nektar Therapeutics has priced an upsized public offering of $325 million, selling 3,532,609 shares at $92.00 per share. This offering is significantly larger than the $250 million equity offering initially planned, as indicated in the 424B5 filing on April 20. The capital raise follows the announcement of positive Phase 2 clinical trial results for rezpegaldesleukin, providing substantial funding for the company's pipeline. However, the pricing at $92.00 per share, below the current market price, implies immediate dilution for existing shareholders and is likely to exert downward pressure on the stock. Traders will be watching the market's reaction to the increased dilution and the company's strategic use of the new capital.
At the time of this announcement, NKTR was trading at $98.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $7.99 to $109.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.